Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14)

Leukemia & Lymphoma
Kuniaki ItohHisashi Wakita

Abstract

The aim of this randomized phase II study was to improve the treatment delays and discontinuations associated with bendamustine use by comparing the effect of Benda-14 (intravenous bendamustine, 120 mg/m2 on days 1 and 15, repeated every 4 weeks for a total of 6 cycles) with those of the standard treatment in relapsed indolent lymphoma and/or mantle cell lymphoma. Forty-six patients were randomly assigned to the treatments from September 2012 to February 2016. Treatment accomplishment rate and median relative dose intensity were similar in both arms: 38 and 63.4% in the Benda-14 arm and 41 and 66.3% in the standard treatment arm, respectively. The overall response rate and median progression-free survival, respectively, were 83% and 21.0 months for Benda-14, and 77% and 15.5 months for the standard treatment. Benda-14 induced favorable responses with less frequent hematological toxicities.

References

Dec 22, 1998·Journal of Cancer Research and Clinical Oncology·K HöffkenS Seeber
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Aug 15, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P SchöffskiA Ganser
Feb 24, 2001·Journal of Cancer Research and Clinical Oncology·R KathK Höffken
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonathan W FriedbergBruce D Cheson
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D Cheson, Mathias J Rummel
Jul 16, 2010·Cancer Science·Ken OhmachiUNKNOWN Japanese Bendamustine Lymphoma Study Group
Mar 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo FedericoMaura Brugiatelli
Aug 1, 2013·The Oncologist·Wolfram Brugger, Michele Ghielmini
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sally F BarringtonBruce D Cheson
Jan 13, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chan Yoon CheahMichael L Wang
Mar 19, 2016·Blood·Brad S Kahl, David T Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.